Inflammatory Cardiomyopathy: A Current View on the
Pathophysiology, Diagnosis, and Treatment

J 2016

Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment

KREJČÍ, Jan, Dalibor MLEJNEK, Dana SOCHOROVÁ and Petr NĚMEC

Basic information

Original name

Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment

Authors

KREJČÍ, Jan (203 Czech Republic, belonging to the institution), Dalibor MLEJNEK (203 Czech Republic, belonging to the institution), Dana SOCHOROVÁ (203 Czech Republic, belonging to the institution) and Petr NĚMEC (203 Czech Republic, guarantor, belonging to the institution)

Edition

Biomed Research International, New York, Hindawi Publishing Corporation, 2016, 2314-6133

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.476

RIV identification code

RIV/00216224:14110/16:00090788

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1155/2016/4087632

UT WoS

000378704900001

Keywords in English

GIANT-CELL MYOCARDITIS; CARDIOVASCULAR MAGNETIC-RESONANCE; VENTRICULAR ENDOMYOCARDIAL BIOPSY; ACUTE VIRAL MYOCARDITIS; ONSET DILATED CARDIOMYOPATHY; HEART-FAILURE ASSOCIATION

Abstract

V originále

Inflammatory cardiomyopathy is defined as inflammation of the heart muscle associated with impaired function of the myocardium. In our region, its etiology is most often viral. Viral infection is a possible trigger of immune and autoimmune mechanisms which contributed to the damage of myocardial function. Myocarditis is considered the most common cause of dilated cardiomyopathy. Typical manifestation of this disease is heart failure, chest pain, or arrhythmias. The most important noninvasive diagnostic method is magnetic resonance imaging, but the gold standard of diagnostics is invasive examination, endomyocardial biopsy. In a significant proportion of cases with impaired left ventricular systolic function, recovery occurs spontaneously in several weeks and therefore it is appropriate to postpone critical therapeutic decisions about 3-6 months after start of the treatment. Therapy is based on standard heart failure treatment; immunosuppressive or antimicrobial treatment may be considered in some cases depending on the results of endomyocardial biopsy. If severe dysfunction of the left ventricle persists, device therapy may be needed.

Citovat

KREJČÍ, Jan, Dalibor MLEJNEK, Dana SOCHOROVÁ and Petr NĚMEC. Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. Biomed Research International. New York: Hindawi Publishing Corporation, 2016, vol. 2016, No 4087632, p. 1-11. ISSN 2314-6133. Available from: https://dx.doi.org/10.1155/2016/4087632.

@article{1353913,
   author = {Krejčí, Jan and Mlejnek, Dalibor and Sochorová, Dana and Němec, Petr},
   article_location = {New York},
   article_number = {4087632},
   doi = {http://dx.doi.org/10.1155/2016/4087632},
   keywords = {GIANT-CELL MYOCARDITIS; CARDIOVASCULAR MAGNETIC-RESONANCE; VENTRICULAR ENDOMYOCARDIAL BIOPSY; ACUTE VIRAL MYOCARDITIS; ONSET DILATED CARDIOMYOPATHY; HEART-FAILURE ASSOCIATION},
   language = {eng},
   issn = {2314-6133},
   journal = {Biomed Research International},
   title = {Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment},
   volume = {2016},
   year = {2016}
}

TY  - JOUR
ID  - 1353913
AU  - Krejčí, Jan - Mlejnek, Dalibor - Sochorová, Dana - Němec, Petr
PY  - 2016
TI  - Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment
JF  - Biomed Research International
VL  - 2016
IS  - 4087632
SP  - 1-11
EP  - 1-11
PB  - Hindawi Publishing Corporation
SN  - 23146133
KW  - GIANT-CELL MYOCARDITIS
KW  - CARDIOVASCULAR MAGNETIC-RESONANCE
KW  - VENTRICULAR ENDOMYOCARDIAL BIOPSY
KW  - ACUTE VIRAL MYOCARDITIS
KW  - ONSET DILATED CARDIOMYOPATHY
KW  - HEART-FAILURE ASSOCIATION
N2  - Inflammatory cardiomyopathy is defined as inflammation of the heart muscle associated with impaired function of the myocardium. In our region, its etiology is most often viral. Viral infection is a possible trigger of immune and autoimmune mechanisms which contributed to the damage of myocardial function. Myocarditis is considered the most common cause of dilated cardiomyopathy. Typical manifestation of this disease is heart failure, chest pain, or arrhythmias. The most important noninvasive diagnostic method is magnetic resonance imaging, but the gold standard of diagnostics is invasive examination, endomyocardial biopsy. In a significant proportion of cases with impaired left ventricular systolic function, recovery occurs spontaneously in several weeks and therefore it is appropriate to postpone critical therapeutic decisions about 3-6 months after start of the treatment. Therapy is based on standard heart failure treatment; immunosuppressive or antimicrobial treatment may be considered in some cases depending on the results of endomyocardial biopsy. If severe dysfunction of the left ventricle persists, device therapy may be needed.
ER  -

KREJČÍ, Jan, Dalibor MLEJNEK, Dana SOCHOROVÁ and Petr NĚMEC. Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. \textit{Biomed Research International}. New York: Hindawi Publishing Corporation, 2016, vol.~2016, No~4087632, p.~1-11. ISSN~2314-6133. Available from: https://dx.doi.org/10.1155/2016/4087632.

Detailed Information on Publication Record